The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints
- PMID: 39018024
- PMCID: PMC11739427
- DOI: 10.14309/ajg.0000000000002953
The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints
Abstract
Introduction: One of the primary goals of the Liver Cirrhosis Network (LCN) is to develop a cohort study to better understand and predict the risk of hepatic decompensation and other clinical and patient-reported outcomes among patients with Child A cirrhosis.
Methods: The LCN consists of a Scientific Data Coordinating Center and 10 clinical centers whose investigators populate multiple committees. The LCN Definitions and Measurements Committee developed preliminary definitions of cirrhosis and its complications by literature review, expert opinion, and reviewing definition documents developed by other organizations. The Cohort Committee developed the study protocol with the input of the steering committee.
Results: The LCN developed a prospective cohort study to describe and predict the rates of incident clinical events pertaining to first decompensation and patient-reported outcomes. The LCN developed a pragmatic definition of compensated cirrhosis incorporating clinical, laboratory, imaging, and histological criteria. Definitions of incident and recompensated ascites, overt hepatic encephalopathy, variceal hemorrhage, bleeding because of portal gastropathy, and hepatocellular carcinoma were also codified.
Discussion: The LCN Cohort Study design will inform the natural history of cirrhosis in contemporary patients with compensated cirrhosis. The LCN Definitions and Measures Committee developed criteria for the definition of cirrhosis to standardize entry into this multicenter cohort study and standardized criteria for liver-related outcome measures. This effort has produced definitions intended to be both sensitive and specific as well as easily operationalized by study staff such that outcomes critical to the LCN cohort are identified and reported in an accurate and generalizable fashion.
Registration: NCT05740358.
Copyright © 2024 by The American College of Gastroenterology.
Conflict of interest statement
Conflicts of interest:
Tapper has consulted for Bausch, Mallinckrodt, Axcella, Novo Nordisk, Ambys, Lipocine, Kaleido, Takeda.
Bajaj has consulted for Merz and Norgine and his institution has received funding from Bausch, Grifols, Axcella, Mallinckrodt and Cosmo.
Goldberg: Research grant support paid to my institution from Gilead and AbbVie
Brown: consulted for Bausch, Mallinckrodt, Ambys, Intercept, Antios, Gilead, Abbvie, Takeda
Verna: grant support to institution from Salix
Terrault: Institutional grant support from GSK, Gilead, Roche-Genentech, Helio Health, DURECT Corp, Eiger Pharmaceuticals.
Hameed: Grants from Gilead, Intercept, Genfit, Pliant, Novo Nordisk, CymaBay; Advisory board for Mallinckrodt, Pleiogenix; Consultant for Gilead, Pioneering Medicine VII, Inc; Stock held in Intercept, Pleiogenix
Khalili: grants to her institution from Gilead Sciences Inc and Intercept Pharmaceuticals and has served as consultant for Gilead Sciences Inc
Parikh: Institutional grant support from Genentech, Exelixis, Exact Sciences, Glycotest, Bayer; Consulting for Eisai, Genentech, Freenome, Exact Sciences
Sharpton: Consulting for Ionis
Diehl: Institutional grant support from Boerhinger-Ingelheim, Madrigal, Novo Nordisk, Novartis, Celgene, Poxel, Enyo, TARGET-NASH, Genfit, Intercept, Galmed, Astra Zeneca, Axcella Health, Hanmi, Viking, NGM, Allergan, Conatus, Terns; Consulting for Allergan, Alderya, Merck, Filcitrine, Sunbio, CASMA, RAPT Therapeutics, Generon, Atria Pharmaceuticals, DILIsym Services
Moylan: Institution grant support from Exact Sciences, GSK; consulted for Boehringer Inghelheim Inc, Novo Nordisk.
Simonetto: Consulted for Mallinckrodt, BioVie and Generon.
Loomba: RL serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myer Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institutions received research grants from Arrowhead Pharmaceuticals, Astrazeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Intercept, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc.
References
-
- Jepsen P, Vilstrup H, Andersen PK. The clinical course of cirrhosis: the importance of multistate models and competing risks analysis. Hepatology 2015;62:292–302. - PubMed
-
- Crabb DW, Bataller R, Chalasani NP, Kamath PS, Lucey M, Mathurin P, McClain C, et al. Standard Definitions and Common Data Elements for Clinical Trials in Patients With Alcoholic Hepatitis: Recommendation From the NIAAA Alcoholic Hepatitis Consortia. Gastroenterology 2016;150:785–790. - PMC - PubMed
Publication types
MeSH terms
Associated data
Grants and funding
- U01 DK130190/DK/NIDDK NIH HHS/United States
- U01DK130181/DK/NIDDK NIH HHS/United States
- U01DK130190/DK/NIDDK NIH HHS/United States
- U01 DK130181/DK/NIDDK NIH HHS/United States
- U01 DK130197/DK/NIDDK NIH HHS/United States
- U01DK130180/DK/NIDDK NIH HHS/United States
- U01 DK130177/DK/NIDDK NIH HHS/United States
- K08 AA028794/AA/NIAAA NIH HHS/United States
- U01DK130134/DK/NIDDK NIH HHS/United States
- U01 DK130221/DK/NIDDK NIH HHS/United States
- U24DK130164/DK/NIDDK NIH HHS/United States
- U01 DK130168/DK/NIDDK NIH HHS/United States
- U01DK130197/DK/NIDDK NIH HHS/United States
- U24 DK130164/DK/NIDDK NIH HHS/United States
- U01 DK130185/DK/NIDDK NIH HHS/United States
- U01DK130113/DK/NIDDK NIH HHS/United States
- U01DK130221/DK/NIDDK NIH HHS/United States
- U01 DK130180/DK/NIDDK NIH HHS/United States
- U01 DK130113/DK/NIDDK NIH HHS/United States
- P50 AA024333/AA/NIAAA NIH HHS/United States
- U01 DK130134/DK/NIDDK NIH HHS/United States
- U01DK130168/DK/NIDDK NIH HHS/United States
- U01DK130185/DK/NIDDK NIH HHS/United States
- U01DK130177/American Diabetes Association
LinkOut - more resources
Medical